ECHO THERAPEUTICS INC 
By Letter Questions Whether Platinum Group Can be Trusted to Protect the Interests of Stockholders
Recommends Stockholders Vote Revised White Proxy Card
Echo Urges Stockholders to Elect Incumbent Directors and Reject Platinum Group's Slate
Recommends Stockholders Vote Revised White Proxy Card
Letter Questions Qualifications of Platinum Group's Board Nominee
Recommends Stockholders Vote Revised White Proxy Card
Letter Questions Platinum Group's Agenda for Waging Costly & Distracting Proxy Contest
Recommends Stockholders Vote Revised White Proxy Card
Letter Highlights Stark Difference Between Echo's Board Slate and Platinum's Board Slate
Recommends Stockholders Vote Revised White Proxy Card
Recommends Stockholders Vote Revised White Proxy Card
Company to Host Conference Call Today, May 9, 2014 at 9:00 AM EDT
Conference Call to begin at 9:00 a.m. EDT
PHILADELPHIA, May 8, 2014/PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless c…… Read More
Company to Host Conference Call Today, March 27, 2014 at 9:00 AM ET
Conference Call to begin at 9:00 a.m. ET
PHILADELPHIA, Pa., March 20, 2014/PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wir…… Read More
PHILADELPHIA, March 6, 2014/PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring s…… Read More
PHILADELPHIA, March 3, 2014/PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring s…… Read More
PHILADELPHIA, Feb. 28, 2014/PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring sy…… Read More
PHILADELPHIA, Feb. 6, 2014/PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring sy…… Read More
PHILADELPHIA, Jan. 15, 2014/PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony®CGM System as a non-invasive, wireless continuous glucose monitoring s…… Read More
PHILADELPHIA, Jan. 14, 2014/PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring sy…… Read More
PHILADELPHIA, Jan. 13, 2014/PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring s…… Read More
Echo to receive a $10 million cash investment from MTIA and Platinum Partners
Company will withdraw the offering identified in recent Form S-1 filing
PHILADELPHIA, Dec. 10, 2013/PRNewswire/ -- Echo Therapeutics, I…… Read More
Symphony meets primary safety and effectiveness endpoints
Company on target to file CE Mark Technical File by year end
PHILADELPHIA, Nov. 26, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medica…… Read More
Conference Call to begin at 9:00 a.m. ET
PHILADELPHIA, Nov. 25, 2013/PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wirele…… Read More
Company to Host Conference Call Today, November 7, 2013 at 9:00 AM EST
Conference Call to begin at 9:00 a.m. ET
PHILADELPHIA, Nov. 1, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wirele…… Read More
PHILADELPHIA, Oct. 3, 2013/PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless, continuous glucose monitoring system, …… Read More
PHILADELPHIA, Sept. 5, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its needle-free Symphony® CGM System as a non-invasive, wireless, continuous glucose monito…… Read More
Conference Call to begin at 9:00 a.m. ET
PHILADELPHIA, Aug. 6, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its non-invasive Symphony® CGM System as a needle-free, wireless c…… Read More
Company Streamlines Cost Structure with Focus on Achieving Critical Milestones
PHILADELPHIA, July 3, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its non-invasive Symphony® C…… Read More
PHILADELPHIA, June 26, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, toda…… Read More
PHILADELPHIA, June 19, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, tod…… Read More
PHILADELPHIA, June 13, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, tod…… Read More
PHILADELPHIA, June 10, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, tod…… Read More
Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on June 7, 2013
PHILADELPHIA, June 6, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony…… Read More
PHILADELPHIA, June 5, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, toda…… Read More
PHILADELPHIA, May 30, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring…… Read More
Data from the trial will support CE Marking
PHILADELPHIA, May 29, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireles…… Read More
Demonstration Followed Stockholders Approval of All Resolutions at Annual Meeting
PHILADELPHIA, May 23, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony®…… Read More
PHILADELPHIA, May 21, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring…… Read More
Demonstration coincides with Symphony's upcoming CE Mark pivotal trial
PHILADELPHIA, May 16, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System …… Read More
PHILADELPHIA, May 10, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring…… Read More
PHILADELPHIA, March 18, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitori…… Read More
PHILADELPHIA, March 15, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitori…… Read More
PHILADELPHIA, March 13, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitori…… Read More
PHILADELPHIA, March 12, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitori…… Read More
PHILADELPHIA, Feb. 6, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose…… Read More
PHILADELPHIA, Jan. 31, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitori…… Read More
PHILADELPHIA, Jan. 31, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitori…… Read More
PHILADELPHIA, Jan. 22, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System as a non-invasive, wirel…… Read More
PHILADELPHIA, Jan. 22, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System as a non-invasive, wirel…… Read More
PHILADELPHIA, Jan. 22, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System as a non-invasive, wirel…… Read More
PHILADELPHIA, Jan. 15, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitori…… Read More
2013 Shaping Up To Be Dynamic Year With Numerous Anticipated Milestones
PHILADELPHIA, Jan. 7, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony…… Read More
PHILADELPHIA, Dec. 27, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today …… Read More
PHILADELPHIA, Dec. 27, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring syste…… Read More
PHILADELPHIA, Dec. 26, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today …… Read More
PHILADELPHIA, Dec. 20, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today …… Read More
PHILADELPHIA, Dec. 20, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today a…… Read More
PHILADELPHIA, Dec. 12, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, is ple…… Read More
PHILADELPHIA, Nov. 29, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today …… Read More
PHILADELPHIA, Nov. 29, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system,…… Read More
PHILADELPHIA, Nov. 27, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today …… Read More
Johnson & Johnson Executive Brings Nearly 30 Years of Supply Chain Leadership
PHILADELPHIA, Nov. 19, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a n…… Read More
PHILADELPHIA, Nov. 9, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today a…… Read More
Company to Host Conference Call Today, November 8, 2012 at 9:00 AM EST
PHILADELPHIA, Nov. 8, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® t…… Read More
PHILADELPHIA, Sept. 4, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics, will present at the Rodman & Renshaw Annual Global Investment Conference.
(Logo: http://photos.prnewswire.com/……Read More
PHILADELPHIA, Aug. 10, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced financial results for the quarter ended June 30, 2012. Echo's Quarterly Report on Form 10-Q, as filed with the SEC, is available through Echo's website at www.echotx.com.
(Logo: h……Read More
Commitment provides resources to move Symphony® tCGM System toward regulatory clearance
PHILADELPHIA, Aug. 9, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Platinum-Montaur Life Sciences, LLC (Montaur) will provide Echo a credit facility of up …… Read More
Data demonstrate that Symphony accurately monitors glucose levels in hospital patients
PHILADELPHIA, Aug. 1, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced positive results from its clinical trial of the Symphony tCGM System in major general surgery…… Read More
PHILADELPHIA, July 11, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that it signed an amended license agreement with Ferndale Pharma Group, Inc. ("Ferndale") that grants Ferndale the right to develop, market and sell Prelude for painless,…… Read More
PHILADELPHIA, June 20, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced the receipt of a notice of allowance for a patent application covering its Prelude SkinPrep System and a notice of issuance for a patent covering its Symphony tCGM System.
Echo Th…… Read More
PHILADELPHIA, June 13, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that, according to a preliminary list of additions posted on June 8, 2012 on www.russell.com, it expects to be included in the Russell Microcap® Index when Russell Investm…… Read More
PHILADELPHIA, June 12, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, presented an expanded analysis of data collected from subjects with either type 1 or type 2 diabetes during its recent clinical trial of its Symphony tCGM System. The data were presented during a…… Read More
Company continues to move Symphony® tCGM System toward commercialization
PHILADELPHIA, May 30, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that David Walton, who has nearly two decades of strategic healthcare marketing experience, has joined Echo…… Read More
PHILADELPHIA, May 29, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics will present at the Jefferies 2012 Global Healthcare Conference.
Dr. Mooney will make a corporate presentation t…… Read More
PHILADELPHIA, May 11, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced financial results for the quarter ended March 31, 2012. Echo's Quarterly Report on Form 10-Q as filed with the SEC is available through Echo's website at www.echotx.com.
Recent C…… Read More
PHILADELPHIA, May 8, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that CEO, Patrick T. Mooney, M.D. will appear on the Wednesday, May 9th airing of the popular Emmy Award-winning television show The Doctors.
Dr. Mooney discusses the benefi…… Read More
PHILADELPHIA, May 2, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced positive results from its clinical trial of the Symphony tCGM System in elective cardiac surgery patients. This study is the first of two studies Echo is conducting in critically i…… Read More
PHILADELPHIA, April 5, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced the issuance of patents covering its Prelude SkinPrep System and a notice of allowance for a U.S. patent covering its Symphony tCGM System.
Patents entitled "Skin Permeation Devic…… Read More
PHILADELPHIA, April 2, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, is pleased to announce that its most recently completed clinical trial was selected for presentation at the 72nd Scientific Sessions of the American Diabetes Association (ADA) which will be held Ju…… Read More
PHILADELPHIA, March 16, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced financial results for the year ended December 31, 2011. Echo's Annual Report on Form 10-K is available through Echo's website at www.echotx.com.
2011 Corporate Highlights:
- Echo a…… Read More
PHILADELPHIA, Jan. 24, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced that it is initiating clinical studies of its Symphony tCGM System in critical care patients. The company expects to complete and announce the results of the studies in the near term.
…… Read MorePHILADELPHIA, Jan. 11, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., Chairman & CEO of Echo Therapeutics, will present at Noble Financial Capital Markets' Eighth Annual Equity Conference.
Dr. Mooney will make a presenta…… Read More
Cash position at year-end approximately $9.2 million
PHILADELPHIA, Jan. 4, 2012 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq: ECTE) today announced that it has received warrant exercises generating a total of approximately $3.6 million in cash proceeds. These warrant exercises bring the company's year-end cash balance to approximately $9.2 million.
"This cash infusion, following the recent positive clinical results for use of our Symphony System, represents impor…… Read More
PHILADELPHIA, Jan. 3, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., Chairman & CEO of Echo Therapeutics, will present at the Biotech Showcase 2012 Conference.
Dr. Mooney will make a presentation to prospective c…… Read More
PHILADELPHIA, Dec. 7, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., Chairman & CEO of Echo Therapeutics, will present at the Oppenheimer 22nd Annual Healthcare Conference.
Dr. Mooney will make a presentation to …… Read More
PHILADELPHIA, Dec. 6, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced positive results from its clinical study of its Symphony tCGM System in patients with type 1 and type 2 diabetes. Data from the study confirm that Symphony successfully monitors t…… Read More
PHILADELPHIA, Dec. 6, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced a registered direct equity financing of approximately $5.4 million by issuing units, with each unit consisting of one share of its common stock and a warrant to purchase 0.4 of a share o…… Read More
PHILADELPHIA, Nov. 15, 2011 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq: ECTE) today announced that it has received a commitment by its largest shareholder, Platinum Partners, for a warrant exercise of $2 million. This warrant exercise will be in addition to the previously announced $1.7 million warrant exercise by Platinum.
"We are very pleased with this warrant exercise as it will allow us to continue the accelerated pace of product development finalization and clinical v…… Read More
Company Continues Steady Progress Toward its Clinical and Operational Objectives
PHILADELPHIA, Nov. 8, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, announced results for the third quarter and nine months ended September 30, 2011. Echo's Quarterly Report on Form 10-Q i…… Read More
Obligation to Redeem Series B Preferred Stock Eliminated
PHILADELPHIA, Nov. 2, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, announced that the Company entered into an agreement with its largest shareholder, Platinum Partners, in which Platinum exercised warrants with an…… Read More
PHILADELPHIA, Oct. 13, 2011 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced that it is initiating a clinical study of its Symphony tCGM System in patients with Type 1 and Type 2 diabetes. The company expects to complete and announce the results of the study in t…… Read More
PHILADELPHIA, Oct. 11, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced that Samir Farah, who has more than fifteen years of medical product design and development experience, has joined Echo Therapeutics' management team at a critical stage in product devel…… Read More
PHILADELPHIA, Oct. 6, 2011 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced positive results from its clinical study of its Symphony tCGM System. Data from the study confirm that Symphony successfully monitors patient glucose levels and continues to demonstrate i…… Read More
PHILADELPHIA, Sept. 20, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the Sixth Annual JMP Securities Healthcare Conference.
Dr. Mooney will m…… Read More
Achievement marks important step in the commercialization of the products
PHILADELPHIA, Sept. 15, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that the company has received Certificates of Registration from the United States Patent and Tradem…… Read More
PHILADELPHIA, Sept. 8, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that it is initiating a clinical study of its Symphony tCGM System. The company expects to complete and announce the results of the study in the near-term.
"Initiating the clinical stu…… Read More
PHILADELPHIA, Sept. 8, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that it is initiating a clinical study of its Symphony tCGM System. The company expects to complete and announce the results of the study in the near-term.
"Initiating the clinical stu…… Read More
PHILADELPHIA, Sept. 7, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the Rodman & Renshaw Annual Global Investment Conference.
Dr. Mooney wi…… Read More
PHILADELPHIA, Aug. 31, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the Stifel Nicolaus Healthcare Conference 2011.
Dr. Mooney will make a …… Read More
Company remains focused on product advancement
PHILADELPHIA, Aug. 12, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced results for the period ended June 30, 2011. Echo's Quarterly Report on Form 10-Q is available through Echo's website at w……Read More
PHILADELPHIA, Aug. 9, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced the unveiling of a much anticipated demonstration video on the Company's website at www.echotx.com. The new video showcases the features and ease of use of the Symphony continuous glu…… Read More
PHILADELPHIA, Aug. 8, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced the receipt of notices of issuance for two patents covering its Symphony tCGM System and notices of registration for the trademarks PRELUDE and SYMPHONY.
Echo Therapeutics received noti…… Read More
Company Continues to Add Depth to Senior Management
PHILADELPHIA, Aug. 2, 2011/PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that Marshall ('Mac') D. Deweese, who has more than fifteen years of experience in blood glucose monitoring systems, has joined Echo …… Read More
Shares to begin trading on Wednesday, June 29, 2011
PHILADELPHIA, June 28, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, is pleased to announce that its common shares have been approved for listing on the NASDAQ Capital Market.
Echo expects its shares to begin trad…… Read More
PHILADELPHIA, June 3, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the Jefferies 2011 Global Healthcare Conference.
Dr. Mooney will make a c…… Read More
PHILADELPHIA, May 23, 2011 /PRNewswire/ --Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, announced that it has received the key components of its next generation Symphony tCGM System design. This newly-engineered design is currently undergoing its final functionality testing.
The updated …… Read More
He joins Patrick T. Mooney, CEO, and Harry G. Mitchell, COO, on the management team as the company expands
PHILADELPHIA, May 16, 2011 /PRNewswire/ --Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that Christopher P. Schnittker, CPA, joined the company as its Chief Financial …… Read More
Company begins 2011 poised to accelerate growth
PHILADELPHIA, May 16, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC BB: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced results for the period ended March 31, 2011. Echo's Quarterly Report on Form 10-Q is available through Echo's website at ww……Read More
FRANKLIN, Mass., May 10, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at SEVEN; Noble Financial Markets' Seventh Annual Equity Conference.
Dr. …… Read More
PHILADELPHIA, May 5, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced the relocation of its corporate headquarters from Franklin, MA to Philadelphia, PA.
The new office is located in the heart of Philadelphia's Center City Business District at 8 Penn Center…… Read More
FRANKLIN, Mass., April 12, 2011 /PRNewswire/ --Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that it received a notice of allowance for U.S. Patent Application No.11/275,038, "System and Method for Continuous Non-Invasive Glucose Monitoring," for the Symphony tCGM System. �…… Read More
FRANKLIN, Mass., March 22, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that John Garibotto and Kenneth Gary, who collectively have nearly fifty years of medical device and diagnostics experience, have joined Echo Therapeutics' senior manag…… Read More
Company begins 2011 poised to achieve national listing and product revenue
FRANKLIN, Mass., March 21, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced results for the year ended December 31, 2010. Echo's Annual Report on Form 10-K…… Read More
FRANKLIN, Mass., March 10, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the ROTH 23rd Annual Growth Stock Conference.
Dr. Moone…… Read More
FRANKLIN, Mass., March 1, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that it won the prestigious 2011 North American Frost & Sullivan Technology Innovation Award in Pharmaceuticals and Biotechnology. Echo received this award in recognit…… Read More
FRANKLIN, Mass., Feb. 17, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, announced that development of the commercially ready Symphony tCGM System is ahead of schedule. The company said that the system will be ready for demonstration in the second quarter …… Read More
New Directors Bring Over 60 Years of Commercial Healthcare Industry Experience
Board Considered Independent for National Exchange Listing
FRANKLIN, Mass., Feb. 15, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced the appointment of William F. G…… Read More
FRANKLIN, Mass., Feb. 10, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that its needle-free drug delivery device, the Prelude System, is featured on the Fast Company magazine website.
The article headlined, "New Drug Delivery Device Will Speed Up…… Read More
Company Receives Comments From FDA That Are Consistent With Expectations
Plans National Exchange Listing and Anticipates Revenue in Third Quarter
FRANKLIN, Mass., Feb. 8, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that the Company's partn…… Read More
FRANKLIN, Mass., Jan. 25, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that the company has launched a corporate Twitter account and corporate Facebook Page. Twitter users can now follow Echo at http://www.twitter.com/echotx and Face…… Read More
FRANKLIN, Mass., Jan. 11, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that its Symphony System was featured in the cover story of Assembly Magazine's January 2011 issue.
"We are pleased to have our Symphony System profiled by Assembl…… Read More
FRANKLIN, Mass., Jan. 7, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the OneMedForum 2011 annual healthcare conference held Ja…… Read More
Company Anticipates Funding is Sufficient Through Symphony Glucose Monitor Pivotal Study
FRANKLIN, Mass., Jan. 6, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that it has raised approximately $2.5 million through a series of private pl…… Read More
FRANKLIN, Mass., Jan. 5, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the Biotech Showcase 3rd Annual Healthcare Conference hel…… Read More
November 29 Issue Profiles Echo's Much-Needed Technology for Continuous Monitoring
FRANKLIN, Mass., Nov. 30, 2010 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that its Symphony System was profiled in the November 29, 2010 issue of Diabete…… Read More
FRANKLIN, Mass., Nov. 11, 2010 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that a 510(k) premarket notification has been submitted to the US Food and Drug Administration (FDA) for its Prelude SkinPrep System and 4% lidocaine cream. Marke…… Read More
Company expects 510k application for Prelude to be filed in the near-term
FRANKLIN, Mass., Nov. 4, 2010 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that it has been awarded a Qualifying Therapeutic Discovery Project (QTDP) grant …… Read More
FRANKLIN, Mass., Oct. 29 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the LifeTech Capital 1st Annual Miami Medical Investors Confer…… Read More
FRANKLIN, Mass., Sept. 23 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the JMP Securities Healthcare Conference being held September…… Read More
Adds Additional Market Opportunities to Company's Platform Technology; Feasibility Studies Indicate Success in Humans
FRANKLIN, Mass., Sept. 21 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that it is beginning a development progra…… Read More
FRANKLIN, Mass., Sept. 16 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick Mooney, M.D., Echo's Chairman and Chief Executive Officer, will present at the prestigious Accredited Members, Inc. (AMI) Fall 2010 Small Cap/Micro Cap Inve…… Read More
FRANKLIN, Mass., Aug. 24 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced the completion of a clinical study of Prelude. This clinical study was designed to evaluate the ability of Prelude to ablate the skin prior to the application o…… Read More
Chairman of Echo Therapeutics Scientific Advisory Board, Dr. Robert Langer, discusses the Company's Technology and Products
FRANKLIN, Mass., May 21 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, announced today that the Chairman of its Scien…… Read More
Company begins transformative 2010 poised to grow revenue and achieve national listing
FRANKLIN, Mass., May 17 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced financial results for the period ended March 31, 2010.
Recent Co…… Read More
Milestone Event Validates Expectations of Near-Term Filing for FDA Clearance and Subsequent Launch
Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude(TM) SkinPrep System for transdermal drug delivery, in collaboration with its strategic partner, Ferndale Pharma Group, Inc., announced today that the first patients were enrolled in a clinical study of its Prelude SkinPrep System. This clinical study is designed to evalu…… Read More
Article Discusses the Importance of Continuous Glucose Monitoring
Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that its Symphony(TM) tCGM System has been featured in a March 31, 2010 online magazine article in Scientific American entitled "This Really Won't Hurt a Bit: Wireless Sensor Promises Diabetics Noninvasiv…… Read More
Article Discusses the Importance of Continuous Glucose Monitoring
Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that its Symphony(TM) tCGM System has been featured in a March 31, 2010 online magazine article in Scientific American entitled "This Really Won't Hurt a Bit: Wireless Sensor Promises Diabetics Noninvasiv…… Read More
Company Plans Clinical Trial in the Near Future
Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that the Company has made a significant advance in the product design of its Symphony tCGM device and that it has developed its next generation electronic component package. This important advance include…… Read More
Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that Patrick T. Mooney, M.D., the Company's Chairman and CEO, will be interviewed on "Steve Crowley's American Scene National Radio" on Tuesday, February 9, 2010 at 9:34 AM ET and Thursday, February 11, 2…… Read More
Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, is pleased to announce the availability of an independent research report that was issued yesterday with a "Strong Speculative Buy" recommendation and a 12 to 18 month price target of $4.50. The report is authored by Ste…… Read More
Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that Patrick T. Mooney, M.D., the Company's Chairman and CEO, will be interviewed on "Steve Crowley's American Scene National Radio" on Wednesday, January 20, 2010 at 9:42 AM ET and Friday January 22, 201…… Read More
Company Plans Clinical Trial Testing and Commercialization in Near-Term
Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that the Company has completed the product development work for its Prelude SkinPrep System and now has the commercially ready product to be used in final clinical trials.
Echo anticipates that no furthe…… Read More
Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that Patrick T. Mooney, M.D., Chairman and Chief Executive Officer, will present at the OneMedPlace Finance Forum 2010 at 11.45 a.m. (PT) on Wednesday, January 13, 2010 at The Sir Fran…… Read More
Patrick Mooney Discusses Transformative Year, Development Progress and Growth Strategy
Echo Therapeutics, Inc. (BULLETIN BOARD: ECTE) , a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude(TM) SkinPrep System for transdermal drug delivery, today announced the availability of a recent interview conducted with Chairman and Chief Executive Officer Patrick T. Mooney, M.D. Stockgoodies.com, a G6 Stocks community, will conduct the interview live at 8:30 a.m. E…… Read More
- Echo Therapeutics to Present at 4th Annual JMP Securities Healthcare Conference... Read More
- Echo Therapeutics Initiates Clinical Study of Its New One-Piece SymphonTM tCGM Biosensor in Type 1 and Type 2 Diabetic Patients... Read More
- Echo Therapeutics Announces Positive Results of a Clinical Study Testing SymphonyTM tCGM System in Patients with Type 1 and Type 2 Diabetes... Read More
- Echo Therapeutics to Present at the New York Society of Security Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference... Read More
- Echo Therapeutics Licenses Needle-free Prelude SkinPrep System to Ferndale Pharma for Enhanced Delivery of Topical Lidocaine... Read More
- Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free SymphonyTM Transdermal Continuous Glucose Monitoring System... Read More
- Echo Therapeutics to Present at 4th Annual JMP Securities Healthcare Conference... Read More
- Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign... Read More
- Echo Therapeutics to Present at Prestigious "Innovations in Diabetes" Conference... Read More
- Echo Therapeutics to Present at Jessup & Lamont 2009 Growth Stock Conference... Read More
- Echo Therapeutics to Present at Rodman & Renshaw 2009 Annual Global Investment Conference... Read More
- Echo Therapeutics Announces Significant Advance in Development of Its One-Piece, Needle Free Symphony tCGM Biosensor... Read More
- Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing... Read More
- Echo Therapeutics Starts Clinical Study of Its Symphony TM Continuous Transdermal Glucose Monitoring System... Read More
- Echo Therapeutics Announces Positive Results with the PreludeTM SkinPrep System, the Next-Generation Skin Permeation Medium for its SymphonyTM Transdermal Continuous Glucose Monitoring System... Read More
- Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for Dermatology Products and Transdermal Drug Delivery Technologies... Read More
- Dr. Anthony P. Furnary Joins Echo Therapeutics Medical Advisory Board... Read More
- Echo Therapeutics Announces Agreement for $2,000,000 Debt Financing... Read More
- Echo Therapeutics Initiates Clinical Study of Its SymphonyTM Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes... Read More
- Echo Therapeutics to Present at RedChip Small-Cap Investor Conference... Read More
- Echo Therapeutics Announces Positive Results of a Clinical Study of its SymphonyTM Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes... Read More
- Echo Therapeutics to Present Clinical Study Results of Its Symphony Transdermal Continuous Glucose Monitoring System at Annual Diabetes Technology Meeting... Read More
- Echo Therapeutics Announces Positive Results from SymphonyTM Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center... Read More
- Echo Therapeutics to Present at JMP Securities Healthcare Investor Conference... Read More
- Echo Therapeutics to Present at Rodman & Rensha's Annual Global Investment Conference... Read More
- Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology... Read More
- Echo Therapeutics Announces Issuance of New Patent for SymphonyTM Transdermal Continuous Glucose Monitoring System... Read More
- Echo Therapeutics Reports Third Quarte 2007 Results... Read More
Stock Information
|
distributed by
|
